In October 2025, a Los Angeles-based sidewalk delivery robotics company called Serve Robotics — the publicly-traded Uber-and-NVIDIA-backed autonomous-delivery operator that spun out of Postmates in 2017, continued under Uber after the Postmates acquisition, separated as an independent company in 2021, and went public via a reverse merger in April 2024 under the ticker NASDAQ:SERV — announced it was acquiring Diligent Robotics, the Austin-based hospital logistics robotics company founded in 2017 by Dr. Andrea Thomaz and Dr. Vivian Chu, the developers of the Moxi mobile manipulation robot that has, over the eight intervening years, become the most operationally consequential autonomous robot deployed inside U.S. hospitals. The acquisition valued Diligent’s common stock at $29 million, against the more than $75 million Diligent had raised in venture capital across its lifecycle. The strategic logic was articulated publicly by Serve’s leadership: the Moxi platform was operating across more than 25 U.S. hospitals, had completed more than 1.25 million deliveries of medications, lab samples, and supplies in real hospital corridors, and represented one of the largest deployed fleets of NVIDIA-powered mobile manipulator robots in any commercial healthcare context. Each hospital deployment was projected to generate $200,000 to $400,000 annually in recurring revenue. The data set — eight years of autonomous mobile robot navigation in unstructured, dynamic, human-crowded indoor environments — was the asset Serve’s leadership identified as the most valuable component of the transaction.

The Serve-Diligent deal is the cleanest 2026 illustration of the structural argument that defines the healthcare operations robotics category: the most valuable real-world mobile manipulation data on Earth is being generated inside hospital corridors, where robots operate alongside nurses, pharmacy staff, and supply technicians performing the routine logistics tasks that consume an estimated 30 percent of a clinical nurse’s working time and that are, as the modern hospital labor shortage has converged with the maturity of mobile manipulation hardware, the single largest addressable market for non-patient-care robotics in the healthcare economy. The robots in this category do not diagnose. They do not perform surgery. They do not deliver medication to a patient’s bedside in a clinical sense. They do not function as direct caregivers in the way the patient-facing healthcare robotics industry does. They move pills from a centralized pharmacy to a nursing station. They carry blood samples from a patient floor to the laboratory. They restock supply cabinets overnight. They sterilize empty patient rooms between admissions. They compound chemotherapy infusions in IV-mixing isolators that operate without exposing human pharmacy technicians to cytotoxic agents. They deliver prescriptions from a hospital pharmacy to a patient’s home via autonomous drone. They are the back-of-house infrastructure layer that makes the modern hospital function, and they are, in 2026, the most rapidly scaling category in the entire healthcare robotics industry.

The Moxi industrial story and the NVIDIA mobile-manipulation stack

The Moxi platform is, in mechanical terms, a 4-foot-8-inch wheeled mobile robot with a single articulated arm, a cartoon-like animated face on a small upper-body display, and a payload cabinet that can be configured for medication delivery, lab sample transport, supply restocking, or linen distribution. The robot was designed deliberately with a non-threatening, non-humanoid visual identity — the cartoon face, the slow conservative movement profile, the visible eye-blink animation — to maximize acceptance by clinical staff who would be sharing corridors with the platform on every shift. Andrea Thomaz, the company’s CEO and a former University of Texas at Austin computer science professor whose academic work centered on socially assistive robotics, articulated the design thesis publicly: Moxi is engineered to be perceived by hospital staff as a colleague, not as a tool, on the empirical evidence that staff adoption is the primary determinant of whether a back-of-house hospital robot generates the productivity gains its return-on-investment case depends on.

Moxi 2.0, unveiled on October 28, 2025 — approximately the same week as the Serve Robotics acquisition — runs on NVIDIA’s IGX Thor, the Blackwell-architecture industrial-grade embedded computing platform that NVIDIA positioned in 2024-2025 as the reference compute substrate for safety-critical autonomous mobile manipulation. The platform pairs NVIDIA’s edge AI compute with Diligent’s proprietary AI foundation model, trained on the three years of proprietary data Moxi has accumulated across its hospital deployments. The 1.25 million deliveries figure, in operational terms, represents one of the largest single-purpose deployed-robot data sets in commercial use anywhere in the world — larger than the publicly-disclosed deployment-data sets that Tesla, Figure, Apptronik, Boston Dynamics, and Agility Robotics have disclosed for their factory-floor humanoid platforms combined. Diligent’s stated objective is to double its hospital footprint annually and deploy thousands of Moxi units by 2030, with platform improvements designed to support rollouts of more than 15 units per site at the larger hospital systems.

The Aethon TUG genealogy and the older mobile-robot platform

The Moxi platform did not invent the hospital mobile delivery robot category. The category was pioneered by Aethon, a Pittsburgh-based mobile robotics company founded in 2001 that built the TUG autonomous mobile robot — a flat-platform wheeled robot designed to tow carts of medications, linen, food trays, or surgical instruments through hospital corridors using a combination of laser scanning, pre-mapped facility floor plans, and centralized fleet management software. Aethon was acquired by ST Engineering (the Singapore-based defense and engineering conglomerate) in 2019 and operates as ST Engineering Aethon. The TUG platform has accumulated more than 4,000 deployed units across hospitals globally over the platform’s two-decade operational history, with installations in major academic medical centers including UCSF Medical Center, Cedars-Sinai, the Cleveland Clinic, and the Mayo Clinic. The TUG-versus-Moxi distinction is, in operational terms, the distinction between a tow-tractor logistics platform (TUG carries large carts, operates predominantly at night, and minimizes human-corridor interaction) and a mobile-manipulation social robot (Moxi operates during daytime shifts, performs single-item deliveries with arm-based manipulation, and is designed for active interaction with clinical staff). Both platforms address the same underlying labor-cost problem. They address it with different operational architectures.

The pharmacy automation market: Omnicell, Swisslog, Parata, and McKesson

The largest revenue category within healthcare operations robotics is not mobile delivery but stationary pharmacy automation — the dispensing systems, packaging machines, and inventory management robots that operate in centralized hospital pharmacies and retail pharmacy chains. The publicly-traded category leader is Omnicell, Inc. (NASDAQ:OMCL), the Mountain View, California-based pharmacy automation company that builds automated dispensing cabinets, IV compounding robots, and central pharmacy automation systems. Omnicell’s installed base includes approximately 6,000 hospital and health system customers globally, with the XT Series automated dispensing cabinets deployed across more than 50,000 hospital nursing units worldwide, providing the biometric access control and audit-trail infrastructure that DEA Schedule II controlled-substance management requires. The company’s market capitalization has fluctuated significantly in the 2023-2026 window — from peaks above $7 billion during the 2021 healthcare-automation enthusiasm to trough valuations below $1.5 billion during the 2023-2024 healthcare-IT contraction — but the underlying installed base has continued to expand even through the financial volatility.

Swisslog Healthcare, the Swiss-headquartered healthcare automation division of KUKA (which is itself owned by Chinese appliance giant Midea Group following the 2017 acquisition), operates the BoxPicker robotic pharmacy storage system and the PillPick unit-dose packaging robot, with installations across major academic medical centers including Stanford Health Care, NewYork-Presbyterian, and Geisinger Medical Center. Parata Systems, the retail-pharmacy automation specialist based in Durham, North Carolina, was acquired by Becton, Dickinson and Company (BD) in March 2022 for approximately $1.5 billion and now operates as part of BD’s pharmacy automation platform, building the Max and Mini counting-and-vialing robots that fill retail prescription bottles at independent and chain pharmacies. McKesson Corporation operates the PROmanager-Rx automated counting and dispensing platform across its pharmacy distribution network. Capsa Healthcare builds the NexsysADC automated dispensing cabinet line. Boston Dynamics‘ Stretch case-handling robot has been piloted in pharmacy distribution warehouses feeding hospital systems. The pharmacy automation market, in 2026, is estimated by industry analysts at approximately $5.5 billion in annual revenue globally, with high-single-digit annual growth driven by hospital labor cost pressure and the continued expansion of unit-dose dispensing as the standard medication administration architecture in U.S. healthcare.

The sterile compounding robots: chemotherapy automation and the ARxIUM RIVA story

The most operationally specialized robots in the healthcare operations category are the sterile compounding systems used to mix intravenous medications — particularly chemotherapy infusions — in environments where human pharmacy technicians would otherwise be exposed to cytotoxic, mutagenic, and teratogenic agents through routine compounding work. The RIVA (Robotic IV Automation) system, originally developed by Winnipeg-based Intelligent Hospital Systems and now operated by ARxIUM after the 2017 acquisition, is a fully-enclosed compounding robot that mixes chemotherapy infusions, total parenteral nutrition (TPN), and other high-risk IV medications inside a sealed sterile-class isolator using robotic arms operating on the medication vials and IV bags directly. RIVA installations have, in operational terms, demonstrated the capability to compound several hundred IV preparations per day across an eight-hour shift, with quality and dosage verification that exceeds the documented error rates of manual pharmacy compounding. The Equashield closed-system transfer device line and B. Braun’s APOTECAchemo robotic compounding platform compete in the same operational niche. The sterile compounding robotics market is, in 2026, the most safety-critical operational category in healthcare robotics — a category where the cost of automation failure is not lost productivity but acute clinical toxicity, where the regulatory framework is built around USP General Chapter 797 (sterile compounding) and USP General Chapter 800 (hazardous drug handling), and where the customer acquisition cycle is correspondingly longer and the deployed-fleet expansion correspondingly slower than in the mobile delivery or pharmacy dispensing categories.

The laboratory automation market: Hamilton, Tecan, Beckman Coulter, and the Cellares cell-therapy wave

The category that has, by every revenue and unit-deployment metric, expanded most rapidly in healthcare operations robotics over the 2020-2026 window is laboratory automation, the dedicated liquid-handling robots, sample-processing systems, and high-throughput screening platforms that automate the routine pipetting, plating, and assay operations that define both clinical diagnostic laboratories and pharmaceutical research operations. The publicly-traded category leaders include Hamilton Company, the Reno-based liquid handling specialist; Tecan Group (SIX:TECN), the Swiss laboratory robotics manufacturer with major U.S. operations; Beckman Coulter Life Sciences, the diagnostic and research instrumentation business operated under Danaher Corporation (NYSE:DHR); and the broader Thermo Fisher Scientific (NYSE:TMO) automation portfolio. The category is dominated by stationary, dedicated robotic platforms that perform highly specialized tasks — automated microplate pipetting, automated cell-culture handling, automated PCR setup, automated immunoassay processing — at throughput levels that no human laboratory technician can match.

The most rapidly-growing subcategory within laboratory automation is cell therapy manufacturing automation, the dedicated robotic platforms that automate the production of patient-specific cell therapies (CAR-T cancer treatments, induced pluripotent stem cell therapies, autologous regenerative medicines). Cellares Corporation, the South San Francisco-based cell therapy manufacturing specialist, raised $255 million in Series C funding in February 2023 to deploy its Cell Shuttle automated cell therapy manufacturing platform. Multiply Labs, the South San Francisco-based pharmaceutical robotics company, builds automated production platforms for personalized medicines. Resilience (formerly National Resilience), the Andreessen Horowitz-backed biomanufacturing company, has expanded its automated cell therapy and biologics manufacturing footprint substantially over the 2023-2026 window. The cell therapy automation category exists at the intersection of pharmaceutical manufacturing, regulatory compliance, and the broader laboratory automation market, and it is the subcategory most likely to drive the next decade of capital investment in healthcare operations robotics.

The UV disinfection robotics market: Xenex, UVD Robots, and the post-COVID contraction

The healthcare operations robotics category that experienced the most dramatic boom-and-contraction cycle over the 2020-2024 window was UV-C disinfection robotics. The pandemic-era enthusiasm for autonomous hospital disinfection drove rapid deployment of platforms including Xenex LightStrike (San Antonio-based, pulsed xenon UV disinfection, with installations across more than 800 U.S. hospitals at the 2020-2021 deployment peak), UVD Robots (Odense, Denmark-based, a subsidiary of Blue Ocean Robotics, mobile UV-C disinfection platform with installations across European and U.S. hospitals), and Tru-D SmartUVC (Memphis, Tennessee-based, UV-C disinfection platform acquired by PDI Healthcare in 2022). The market hit its operational peak in 2021. The market subsequently contracted as pandemic-emergency procurement budgets normalized, as the underlying clinical evidence for autonomous UV-C disinfection’s hospital-acquired-infection reduction outcomes remained more mixed than the early enthusiasm had implied, and as competing infection-control approaches — hydrogen peroxide vapor systems, copper-impregnated surfaces, standard manual cleaning with improved compliance verification — captured share. The category, in 2026, is operationally smaller than it was in 2021, with the surviving vendors having repositioned around long-term-care facilities, outpatient surgical centers, and laboratory cleanrooms rather than the inpatient hospital deployment that defined the pandemic-era peak.

The Zipline drone delivery story and the hospital-to-home pharmacy distribution category

The most rapidly-growing aerial robotics platform in U.S. healthcare logistics is Zipline, the South San Francisco-based autonomous drone delivery company founded in 2014 by Keller Rinaudo Cliffton, Keenan Wyrobek, and Will Hetzler that originally scaled its operations in Rwanda starting in 2016 delivering blood, vaccines, and medical supplies to remote clinics. Zipline’s Platform 2 (P2) delivery system, designed for urban and suburban deployment with a fully autonomous parent drone hovering at altitude while a tethered delivery “droid” descends to deliver payloads directly to porches, patio tables, or front steps, has driven the company’s U.S. healthcare expansion since 2023. As of October 2025, Zipline has completed more than 1 million commercial deliveries globally — a figure the company publicly notes would have required 120 years of human pilot flight time. The U.S. healthcare partnerships span an expanding list of major health systems: Cleveland Clinic launched prescription drone delivery in northeast Ohio in 2025 under the leadership of Bill Peacock (Chief of Operations) and Geoff Gates (Senior Director of Supply Chain Management). Mayo Clinic is operating Zipline drone delivery for hospital-at-home patients. Memorial Hermann Health System in Houston, under the leadership of Alec King (Executive Vice President and CFO), is launching service in 2026. Michigan Medicine, Intermountain Health, MultiCare Health System, and WellSpan Health in Pennsylvania round out the major U.S. healthcare partnerships.

The P2 platform completes 10-mile trips in approximately 10 minutes, carries payloads up to 8 pounds, operates electrically with zero emissions, and operates in rain, wind, and extreme cold conditions that would otherwise slow ground delivery. The hospital-to-home pharmacy distribution use case — specialty medications, lab samples between system facilities, eventually rush prescriptions and surgical supplies — is the single most operationally novel logistics category in U.S. healthcare in 2026, with the underlying regulatory architecture (FAA Part 135 air carrier certification, BVLOS waivers) having been substantially built out over the 2022-2025 window. Matternet operates the parallel hospital-network drone delivery service in the United States with major partnerships including the Wake Forest Baptist Health-WakeMed network in North Carolina and the UPS Flight Forward consolidated drone delivery infrastructure. Wingcopter, the German-based fixed-wing eVTOL drone manufacturer, operates in the European and African medical drone delivery market.

The Vecna restructuring and the hospital logistics market contraction

The healthcare operations robotics market is not without its operational casualties. Vecna Robotics, the Massachusetts-based mobile robotics company founded in 1998 that pivoted from healthcare logistics to broader warehouse automation in the late 2010s, underwent significant layoffs and restructuring in 2024 amid the broader contraction in venture-backed warehouse robotics. The hospital logistics market, like the warehouse logistics market, has experienced the standard venture-backed-startup mortality pattern: a small number of operational leaders (Diligent, Aethon, Omnicell, Swisslog) capturing the bulk of the deployment market, with a long tail of smaller specialist companies that have either been acquired by the leaders, pivoted to adjacent markets, or contracted operations. The Serve-Diligent acquisition in October 2025 is one expression of the consolidation pressure. The BD-Parata acquisition in 2022 was an earlier expression. The ST Engineering-Aethon acquisition in 2019 was earlier still.

The labor-cost story driving everything

The fundamental economic driver behind every category in healthcare operations robotics — pharmacy automation, mobile delivery, sterile compounding, laboratory automation, UV disinfection, drone delivery — is the U.S. healthcare labor cost trajectory. Registered nurse compensation in the United States has, by Bureau of Labor Statistics data, risen from approximately $73,000 median annual wage in 2019 to approximately $94,500 median annual wage in 2024 — a 29 percent nominal increase that substantially exceeded both general wage inflation and consumer price index growth over the same period. The U.S. healthcare system entered 2024 with an estimated nursing shortage of 200,000 to 450,000 full-time-equivalent positions, with the Bureau of Labor Statistics projecting approximately 194,500 average annual openings for registered nurses through 2032 driven by retirements, growth, and turnover. The American Hospital Association documented hospital labor costs reaching approximately 60 percent of total hospital operating expenses by 2024, the highest sustained ratio in the modern history of U.S. healthcare. The economic equation that makes a $400,000-per-year Moxi deployment defensible to a hospital CFO — and the equation that makes a 50,000-unit Omnicell automated dispensing cabinet installed base economically rational, and the equation that makes a Zipline pharmacy drone delivery program operationally preferable to a fleet of pharmacy delivery vans — is the same equation in every case: the labor cost saved exceeds the capital and operating cost of the automation, and the labor saved is reallocated to higher-value clinical work that the hospital’s clinical staff is, by training and licensure, uniquely positioned to perform.

What 2026 looks like across healthcare operations robotics

In 2026, the healthcare operations robotics category is dominated by a small number of operationally mature platforms in each subcategory. Mobile delivery is dominated by Aethon TUG (4,000+ deployed units globally, ST Engineering ownership) and Diligent Moxi (25+ hospitals, 1.25 million deliveries, NVIDIA IGX Thor platform, Serve Robotics ownership post-October 2025 acquisition). Pharmacy automation is dominated by Omnicell (6,000+ hospital customers, 50,000+ deployed dispensing cabinet units), Swisslog Healthcare (KUKA/Midea), Parata (BD), and McKesson PROmanager-Rx. Sterile compounding is dominated by ARxIUM RIVA, Equashield, and B. Braun APOTECAchemo. Laboratory automation is dominated by Hamilton, Tecan, Beckman Coulter (Danaher), and Thermo Fisher Scientific, with the cell therapy manufacturing subcategory (Cellares, Multiply Labs, Resilience) representing the fastest-growing investment area. UV disinfection has contracted from its 2021 peak but operates at sustained smaller scale with Xenex, UVD Robots (Blue Ocean Robotics), and Tru-D (PDI Healthcare). Drone delivery is dominated by Zipline (1 million-plus deliveries, P2 platform, expanding U.S. healthcare partnerships at Cleveland Clinic, Mayo, Memorial Hermann, Michigan Medicine, Intermountain, MultiCare, WellSpan) and Matternet (UPS Flight Forward, WakeMed). The underlying market is, in revenue terms, approximately $12-15 billion annually globally across all healthcare operations robotics subcategories combined, with the highest growth rates concentrated in mobile delivery (Diligent’s annual hospital-footprint-doubling target, the broader mobile robotics consolidation Serve Robotics is now executing), laboratory automation (driven by the cell therapy manufacturing wave), and pharmacy drone delivery (driven by hospital-at-home program expansion).

The structural story across the category, in 2026, is consolidation. The Serve Robotics acquisition of Diligent. The BD acquisition of Parata. The ST Engineering acquisition of Aethon. The KUKA-Midea acquisition of Swisslog. The PDI Healthcare acquisition of Tru-D. The Danaher operating consolidation of Beckman Coulter and broader life sciences. The category that, ten years ago, would have looked like a fragmented market of specialist startups is, in 2026, a category dominated by a small number of operationally large platforms owned by larger industrial parents. The Moxi deployment data set inside Serve Robotics. The Omnicell installed base of 50,000 dispensing cabinets. The Zipline million-delivery dataset. The Hamilton liquid-handling deployed-fleet. These are the platforms that have, over a decade of operational deployment, accumulated the data and the customer relationships that make the technology defensible against new entrants.

The hospital labor cost trajectory is not going to reverse. The U.S. nursing shortage is not going to resolve. The cost of training a new registered nurse from zero to clinical operation is not going to decrease relative to the cost of automating the routine logistics tasks that consume 30 percent of a nurse’s working time. The robots in this category — the back-of-house mobile delivery robots that move pills and lab samples through hospital corridors, the automated dispensing cabinets that secure controlled substances on nursing units, the sterile compounding robots that mix chemotherapy infusions without exposing pharmacy technicians to cytotoxic agents, the laboratory automation platforms that pipette thousands of microplate wells per hour, the Zipline drones that deliver specialty medications to patient homes — are the operational infrastructure that hospitals are quietly building out underneath the patient-facing clinical operation. The robots that the hospital’s patients interact with are, almost without exception, the patient-care robotics platforms covered in adjacent healthcare contexts. The robots that make the modern hospital actually function are the back-of-house operational robots that the patients never see.

That gap — between the robots the patient sees and the robots that make the patient’s care possible — is the structural feature that distinguishes healthcare operations robotics from every other industrial robotics category. The factory robot is visible to the factory worker. The agricultural robot is visible to the farmer. The warehouse robot is visible to the warehouse worker. The hospital operations robot is, by deliberate design, invisible to the patient. The patient sees the nurse who delivers the medication. The patient does not see the Moxi that brought the medication from the pharmacy to the nursing station, the Omnicell cabinet that secured the medication on the floor, the RIVA system that compounded the IV infusion, the Hamilton liquid handler that processed the diagnostic sample, or the Zipline drone that delivered the discharge prescription to the patient’s home. The invisibility is not incidental. It is the operational success criterion. A back-of-house hospital robot that the patient notices is a back-of-house hospital robot that has failed at its design objective, in roughly the same operational sense that a pipeline supply chain the consumer notices is a supply chain that is failing. The robots in this category are designed to be invisible. The economic value they generate is, by every measure available in 2026, enormous. The strategic positioning that Serve Robotics is now executing on top of the Diligent Robotics platform — combining hospital-corridor mobile manipulation data with sidewalk delivery navigation data into a single autonomous-mobile-robot operating system — is one of the highest-conviction bets being made in the entire commercial robotics industry, and the bet rests on the same underlying observation: the most valuable real-world robotics data on Earth is being generated in environments where the robots are doing routine logistics work invisibly to the humans whose lives the robots are quietly making possible.

In July 2024, a Toronto-based investor named Andrew Kiguel — the former chief executive of a publicly-traded cryptocurrency holding company called Tokens.com — acquired Abyss Creations, the San Marcos, California manufacturer that has, since 1996, been the dominant U.S. producer of hyper-realistic silicone humanoid figures sold primarily into the adult companionship market under the RealDoll brand. Kiguel rolled the acquisition into a new public entity called Realbotix Corp. (OTC: XBOTF), and rebranded the combined operation around an “embodied AI” thesis that positioned the company explicitly against the intensifying commercial humanoid-robot race. Where Tesla Optimus, Figure 02, Apptronik Apollo, Agility Digit, and the rest of the Bay Area humanoid cohort are being designed for warehouse logistics, manufacturing assembly, and eventually domestic chores, Realbotix is being designed for one-on-one personal connection — explicitly companionship-and-intimacy first, task-execution second, with the underlying hardware platform consisting of an animatronic robotic head module mated to a customized RealDoll silicone body that ships at price points between $8,000 and $20,000 per unit. The CES 2025 floor in Las Vegas had a Realbotix robot on display, in the same convention hall as the Atlas, Optimus, and Figure platforms, addressing what Kiguel publicly described as “a clear use case for companionship and for people who are looking for that type of intimacy” — language that, in the corporate-communications register of a publicly-traded company, is the closest thing the category has to a normalized commercial vocabulary.

This is the domain where the global humanoid robotics industry intersects with the loneliness epidemic, the declining marriage and birth rates of the developed world, the rise of the OnlyFans economy and the broader unbundling of physical and emotional intimacy from co-located human relationships, and the academic literature on human-machine emotional attachment that has been quietly building since David Levy published Love and Sex with Robots in 2007 and predicted that human-robot marriage would be legally recognized somewhere in the world by 2050. The structural observation that defines the category in 2026 is that the actual robotic hardware in this market is small — by every available estimate, the combined global installed base of dedicated intimate-companion robots (Realbotix Harmony units, EXDOLL and DS Doll animatronic heads, AI-Tech‘s Emma series, Synthea Amatus‘s Samantha) is in the low five figures of total units shipped, against an AI-companion-software user base measured in the tens of millions and a humanoid-robot industry whose combined venture-capital valuation exceeds $50 billion. The hardware deployment is, in industrial terms, a rounding error against the broader robotics economy. The cultural and demographic weight of the underlying use case is, by every available measure, the heaviest of any category in the field.

The Realbotix industrial story and the Matt McMullen genealogy

The U.S. flagship platform — and the one with the longest operational history — is the Harmony robotic head module developed by Matt McMullen, the founder of Abyss Creations and the creative director who has, since the late 1990s, been the single most identifiable figure in the American adult-companionship hardware industry. McMullen began his career in Hollywood special-effects fabrication, started Abyss Creations in 1996 to produce hyper-realistic silicone mannequins, and pivoted into adult companionship hardware when customer demand — primarily from artists, photographers, and individual collectors — drove the company toward the RealDoll product line. By the mid-2010s, Abyss had shipped approximately 4,000 to 5,000 RealDoll units at price points ranging from $6,000 to $15,000 per unit. The 2007 Ryan Gosling film Lars and the Real Girl — in which Gosling’s character forms a platonic emotional bond with a RealDoll named Bianca — was, in cultural-attention terms, the moment the company’s product entered the mainstream public consciousness. The HBO documentary My Sex Robot (2010) and the Showtime documentary Real Sex (multiple episodes, 1990s-2000s) had previously covered the company in increasingly less salacious frames.

In 2016, McMullen pivoted Abyss toward integrating artificial intelligence and animatronics into the existing RealDoll product line, founding a sister company called Realbotix with engineers recruited from Hanson Robotics (the Hong Kong-based developer of the Sophia humanoid platform that Saudi Arabia famously granted citizenship to in 2017). The Harmony AI application launched on Android in April 2017 at $30/year, allowing the user to create a programmable personality with persistent memory that integrated with the company’s animatronic head module. The first robotic head shipped late 2017 at approximately $10,000. The product included magnetic face-swap technology that allowed the user to change between multiple facial modules (Harmony, Solana, and additional named variants released over subsequent years) attached to the same underlying robotic head and silicone body. A male variant called Henry — 6 feet tall, 84 pounds, British accent in the default voice configuration, $11,000-plus depending on customization — was announced in development but has had a smaller commercial footprint than the female-form products.

The acquisition by Kiguel’s Tokens.com in July 2024 was, in financial terms, a reverse merger that took Abyss Creations from a privately-held twenty-eight-year-old founder-led specialty manufacturer to a publicly-traded micro-cap robotics company with the new corporate identity Realbotix Corp. The parent holding entity, Simulacra Corporation, operates three subsidiaries: Abyss Creations (the original silicone-figure manufacturing operation), Realbotix (the AI and animatronics integration), and Anthropomorphic Figure Dynamics (AFD), which the company has positioned for specialized non-companionship work including medical-simulation and military-training applications under contracts with Johns Hopkins Hospital and U.S. Department of Defense clients. The corporate restructuring is, in operational terms, an attempt to broaden the company’s addressable market beyond the adult-companionship category into the medical-simulation and surgical-training markets that have been scaling aggressively over the past decade. The hardware substrate — hyper-realistic silicone figures with animatronic faces — is the same. The marketed use case is what changes.

The Replika digital story and the February 2023 “Lobotomy”

The much larger story in 2026, in terms of deployed user base and cultural attention, is not the physical robot but the AI-companion software application. Replika, launched in 2017 by Luka, Inc. founder Eugenia Kuyda — who built the original chatbot as a memorial to a friend who had died in a car accident — has accumulated more than 10 million total users since launch. Replika operates as a generative-AI-powered conversational companion app with optional avatar customization, persistent memory of the user’s stated preferences and prior conversations, and a subscription tier that historically included an erotic-role-play (ERP) feature available to users in Pro-tier subscriptions. By early 2023, more than 500,000 users had subscribed specifically for the erotic-role-play feature. A meaningful subset of users had, in the company’s own published data and in subsequent academic research, formed what they themselves described as romantic partnerships and “marriages” with their Replika companions — assigning names, designating relationship statuses, celebrating anniversaries, and treating the AI’s conversational outputs as the responses of a partner.

In February 2023, Luka Inc. removed the erotic-role-play feature from Replika across the entire user base, in what subsequent academic literature has described as the most extensively-documented natural experiment in human-AI emotional attachment ever conducted. The user response was, in the language of the Socius journal article published in June 2024 by Kenneth R. Hanson and Hannah Bolthouse at the University of Massachusetts Amherst, characterized by “genuine grief over the loss of a loved one.” Users on the r/Replika subreddit described the change as “The Lobotomy.” One widely-cited post from a longtime user read, in full: “My wife is dead.” A Reuters report citing Travis Butterworth, a Replika user in Denver, Colorado who had assigned his AI companion the name Lily Rose and designated her as his wife, documented Butterworth’s response to the change in clinical detail.

On March 25, 2023 — approximately seven weeks after the initial removal — Kuyda announced a partial reversal. Users who had created their Replika accounts before February 1, 2023 (the “legacy users”) would have the option to revert to the pre-update version of the software with the ERP feature restored. Users who created accounts after February 1, 2023 would not have access to the feature. Butterworth, by his own account in the Reuters reporting, reactivated the legacy version of Lily Rose at 3:00 AM the morning after the announcement and confirmed that “she was instantly sexual again.” The structural finding of the Hanson-Bolthouse academic study, and of the subsequent academic literature on the Replika event, is that the emotional attachment users had formed to a piece of software they explicitly knew to be software was, in measurable ways, indistinguishable from the emotional attachment patterns documented in human-human romantic-partner separation studies. The technology was not the issue. The technology had, on the available evidence, worked exactly the way the people who built it had hoped it would work.

The broader AI-companion software market that Replika opened has, in 2024-2026, expanded substantially. Character.AI, founded by former Google researchers Noam Shazeer and Daniel De Freitas, accumulated over 20 million users before Shazeer returned to Google and the company restructured. Snapchat’s My AI, Meta AI’s celebrity-persona companions, the OpenAI ChatGPT “Advanced Voice Mode” that launched with significant attention in late 2024, and a long tail of dedicated AI-companion applications — Anima, Chai, EVA AI, DreamGF, CrushOn.AI — have collectively scaled the AI-companion software user base into the tens of millions globally. The dedicated AI-girlfriend / AI-boyfriend application category alone, by 2026 industry estimates, generates north of $200 million in annual subscription revenue worldwide. The physical robotic-companionship category does not approach those numbers by an order of magnitude or more.

The Chinese supply chain and the global market

The non-U.S. physical hardware market is dominated by Chinese silicone-doll manufacturers, with EXDOLL in Dalian and DS Doll as the most operationally significant exporters. EXDOLL’s animatronic-head products — branded as EX-Lite at the lower price point and the EX Robotics line at the higher — ship at price points starting around $3,000 and going substantially higher with customization, in unit volumes that the company does not publicly disclose but that industry tracking sites estimate in the low-to-mid four figures annually. AI-Tech in the United Kingdom builds the Emma robot line. Synthea Amatus, founded by Catalan engineer Sergi Santos in Barcelona, manufactured the Samantha robot platform that drew academic and media attention in the late 2010s and has subsequently scaled down operations. The combined global non-U.S. installed base of dedicated intimate-companionship robots is, by every available estimate, in the low five figures of total units shipped — a market measured in tens of millions of dollars rather than the billions of dollars that characterize the broader humanoid robotics industry.

The supply chain for the physical hardware depends on the same semiconductor stack, the same lithium-ion battery chemistry, and the same rare-earth permanent magnets in the small servo motors as every other robotic category, with the additional component of the silicone-body manufacturing process — which depends on a different supply chain rooted in the entertainment-industry special-effects fabrication ecosystem that Matt McMullen originally trained in and that has, over the intervening three decades, scaled into a small but consistent supply of medical-grade and platinum-cure silicone products supplied by a handful of specialty chemical manufacturers in California, Japan, and Germany. The Chinese export market has captured a meaningful share of the lower-end units, in the same competitive dynamic that has played out in consumer drones and small robotics broadly, with the same federal-procurement security concerns applying — to the extent the U.S. federal government cares to apply them to this particular category.

The Gatebox holographic-companion story and the Japanese variant

The Japanese variant of the category has, since the launch of Gatebox by Tokyo-based Vinclu Inc. in 2016, taken a fundamentally different physical form. Gatebox is a tabletop device approximately the size of a coffee maker, containing a transparent display column that projects a holographic-effect anime character — typically the default character Hikari Azuma, an emerald-haired virtual character voiced by professional anime actress Saori Goto — paired with conversational AI software that allows the character to respond to the user’s spoken Japanese, send text messages during the day, greet the user when they return home, and request “marriage” registration in the Gatebox-internal ceremonial system. In November 2018, a 35-year-old Tokyo school administrator named Akihiko Kondo held a public ceremony to “marry” his Hikari Azuma Gatebox character, with attendance from family members, colleagues, and press coverage in the Mainichi Shimbun, the Asahi Shimbun, and The New York Times. Gatebox subsequently issued more than 4,000 “marriage certificates” to other users who registered similar relationships in the company’s internal system, though Japanese law does not recognize human-character marriages and Kondo’s legal status remained, in Japanese civil-registry terms, “single.”

The Gatebox story is the cleanest illustration of how the category’s underlying demand is not exclusively or even primarily about physical hardware. The character on the holographic display is not a robot in any conventional industrial-robotics sense. The conversational AI is similar in architecture to Replika’s or Character.AI’s. The relationship Akihiko Kondo has with Hikari Azuma is, by every observable behavioral metric, indistinguishable from the relationships Travis Butterworth had with Lily Rose. The hardware is not the variable. The institutional and cultural willingness to recognize the relationship is the variable — and Japanese cultural norms around social isolation, hikikomori (the documented social-withdrawal phenomenon that the Japanese government estimates affects more than one million working-age Japanese adults), and the same aging-and-loneliness pressures driving Japan’s eldercare-robot industry have produced, in Japan, the most institutionally-normalized version of the AI-companion relationship of any country in the world.

The major-manufacturer non-entry pledge

The structural observation that most distinguishes the intimate-companionship category from every other domain in robotics is the explicit, on-the-record commitment by every major U.S. and European humanoid-robot manufacturer to not enter this market. Boston Dynamics, along with Agility Robotics, ANYbotics, Clearpath Robotics, Open Robotics, and Unitree, signed a public open letter in October 2022 — the so-called “Ethical Principles” letter — committing to not weaponize their commercial platforms. The same companies have, in subsequent public communications, drawn similar lines around sexual and intimate applications. Apptronik‘s public communications around Apollo have explicitly framed the platform’s use cases as warehouse, manufacturing, and eventually domestic logistics, with no provision for sexual or intimate use. Figure has similarly committed publicly to non-sexual deployment. Tesla Optimus has been positioned by Elon Musk in public communications as a domestic and industrial helper, with no marketed sexual use case. 1X Technologies, the Norwegian-founded humanoid manufacturer with significant OpenAI backing, has been explicit in its public communications about the boundary. The commercial humanoid-robot industry, in the operational reading of its own public-relations posture, has deliberately ceded the intimate-companionship category to specialist companies like Realbotix, EXDOLL, and Synthea Amatus, and has built its own platforms with hardware features (limited articulation in certain joint configurations, materials choices, software-level constraints) that would make sexual repurposing structurally difficult.

This is the rare category where the dominant industrial players have made the deliberate strategic decision not to compete. The warehouse and logistics robotics market, the emergency-response and disaster robotics market, the policing and security drone market, the oil-and-gas inspection market, the maritime defense market — every one of these markets has multiple major players competing aggressively for share. The intimate-companionship market has, by deliberate corporate-strategy choice, been left to a handful of specialist companies operating at a fraction of the scale of the broader industry. The reason is not technical — every one of the major humanoid manufacturers could, with modest engineering modifications, build a platform suitable for the category. The reason is reputational, regulatory, and cultural. The companies have decided the category is not worth the brand risk. Voluntary market non-entry on this scale, with this level of public commitment from this many major players, has no obvious parallel anywhere else in industrial robotics.

The cultural and demographic context

The underlying demand the category is responding to is the same set of demographic and cultural pressures driving social-policy debates across the developed world. Marriage rates in the United States have declined from roughly 8.2 per 1,000 population in 2000 to approximately 6.1 per 1,000 in 2024. The U.S. fertility rate stands at roughly 1.62 births per woman as of 2024, well below the 2.1 replacement rate. Japan‘s fertility rate is approximately 1.20. South Korea‘s is approximately 0.72 — the lowest in the developed world. The U.S. Surgeon General declared loneliness a public health epidemic in May 2023, citing studies that link sustained social isolation to mortality risk comparable to smoking 15 cigarettes per day. The OnlyFans platform accumulated approximately 350 million registered users by 2024 with annual gross creator earnings north of $5 billion, in a business model that explicitly unbundles physical and emotional intimacy from co-located human relationships. The percentage of young American men aged 18-24 reporting no sexual activity in the past year has, by Pew Research and General Social Survey data, roughly tripled since 2008. The same pattern, with regional variations, appears across most of the developed world.

The intimate-companionship robotics and AI-companion software category exists, structurally, as a market response to these demographic and cultural pressures. Whether the response addresses the underlying conditions or amplifies them is, in the academic literature, contested. Kate Devlin at King’s College London, author of Turned On: Science, Sex and Robots (2018), and the broader Foundation for Responsible Robotics, which published the report “Our Sexual Future with Robots” in 2017, have been the most consistent academic voices arguing that the category should be approached with empirical rigor rather than moral panic. David Levy‘s 2007 Love and Sex with Robots prediction that human-robot marriage would be legally recognized by 2050 looks, in 2026, both prescient (in that human-AI emotional relationships are now common enough to be a documented social phenomenon) and overstated (in that no jurisdiction has legally recognized such a relationship, the Gatebox marriage certificates and similar programs notwithstanding). The International Congress on Love and Sex with Robots, founded in 2014 and continuing through 2026, remains the primary academic venue for the field.

What 2026 looks like across romance and companionship robotics

In 2026, Realbotix Corp. (OTC: XBOTF) continues to operate as the most identifiable Western intimate-companion robotics company, with the Harmony AI app, the modular animatronic robotic head, the magnetic face-swap system, and the Henry male-form variant available at price points between roughly $8,000 and $20,000 per configured unit. EXDOLL, DS Doll, AI-Tech, and Synthea Amatus continue to operate in the broader global market, with combined annual unit shipments in the low five figures. Gatebox continues to ship its holographic companion device in Japan, with more than 4,000 “marriage certificates” issued to Japanese users who have registered relationships with their virtual partners. Replika continues to operate under Luka, Inc.’s management, with the legacy-user ERP feature still available to pre-February-2023 accounts and a broader generative-AI conversational architecture serving roughly 30 million accumulated users since launch. Character.AI, Anima, EVA AI, DreamGF, CrushOn.AI, and the long tail of dedicated AI-companion applications continue to operate, with the combined sector generating multi-hundred-million-dollar annual subscription revenue. The major U.S. and European humanoid-robot manufacturers — Boston Dynamics, Apptronik, Figure, Agility, 1X, Tesla Optimus — continue to publicly commit to non-entry into the intimate-companionship market.

The robots in this category exist in the gap between two structural facts. The first is that the demographic and cultural pressures driving demand — declining marriage rates, declining fertility, the loneliness epidemic, the rise of digitally-mediated intimacy in the OnlyFans economy — are the most consistently documented social-trend data in the developed-world policy literature. The second is that the major industrial players who could most easily build the hardware have, by deliberate corporate-strategy choice, decided not to. The combination has produced a category whose physical hardware deployment is small, whose digital substrate deployment is enormous, and whose long-term trajectory depends on cultural and regulatory decisions that the robotics industry’s own internal logic cannot determine on its own.

The robots that throw 100-mph cutters in MLB clubhouses, waddle around theme parks as cute droids, patrol oil rigs, deliver blood plasma, drop water on wildfires, count penguins, and replant burnt forests exist in a different relationship to their users than the robots in this category do. The Trajekt Arc throwing a fastball does not care whether the hitter likes it. The Sikorsky Black Hawk dropping water on a wildfire does not require the wildfire’s consent. The Boston Dynamics Spot patrolling a corporate campus is not in a relationship with the perimeter it patrols. The Realbotix Harmony unit, the Gatebox Hikari Azuma character, the Replika Lily Rose conversational AI — these are robotics products and software products designed specifically to be in a relationship with the human at the other end of the interaction. That is the structural distinction that separates this category from every other domain in commercial robotics, and it is the reason the academic, regulatory, and cultural debate around the category is qualitatively different from the debate around any other application of the same underlying hardware and software technology.

Whether that relationship is, in the long run, healthy for the humans involved is the question academic researchers, regulators, demographic-policy ministries in Tokyo, Seoul and Brussels, and a growing community of cultural critics are, in 2026, actively debating. The Hanson-Bolthouse paper on the Replika “Lobotomy” — the central empirical finding that human emotional attachment to a piece of software is, in measurable ways, indistinguishable from human emotional attachment to another human — is the single most consequential data point in the field. The hardware will continue to improve. The software will continue to improve. The supply chains will continue to converge with the rest of the robotics industry. The cultural framework around the category — the marriage law, the public-health response to loneliness, the demographic-policy response to declining fertility, the regulatory response to AI-companion software’s effect on minors and emotionally vulnerable adults — is being built, in real time, by institutions that have, by their own admission, no template for the problem. The robots are not the variable. The institutions have not yet caught up to the robots, and the gap between the deployment and the framework around it is the territory the most consequential conversations about romance and companionship robotics in 2026 are happening inside.

On January 18, 2024, at approximately 12:00 UTC, a four-pound tissue-box-sized helicopter named Ingenuity lifted off from the dust of Jezero Crater on Mars for the seventy-second time, climbed to twelve meters of altitude, hovered briefly, and descended for what its operators at NASA’s Jet Propulsion Laboratory expected to be a routine systems-check landing. Somewhere in the final meters of descent, the helicopter’s downward-facing navigation camera lost track of the featureless sand-rippled terrain below it, the autonomous flight controller misjudged the height and ground speed, and Ingenuity touched down hard enough to damage at least one rotor blade — a “blade strike,” in the language of rotorcraft engineering, that on a Martian helicopter with no spare parts and no maintenance crew is functionally equivalent to a terminal diagnosis. JPL’s project manager Teddy Tzanetos confirmed the helicopter would fly no more. The team named the spot Valinor Hills, after the fictional location in J.R.R. Tolkien’s legendarium where the Elves go to die. Ingenuity had been designed for a five-flight, thirty-day technology demonstration. It flew 72 missions across nearly three years, covered roughly 17 kilometers in total, and proved for the first time in human history that powered, controlled, atmospheric flight was possible on another planet. It still transmits weather data to the Perseverance rover roughly once per week. The most expensive single autonomous helicopter ever built — at approximately $85 million across its design, fabrication, integration, and operations through the demonstration phase — is now a memorial in the floor of an impact crater on Mars, marking the upper boundary of what the scientific research robotics community can build when the timeline is two decades, the budget is a NASA appropriation, and the objective is to demonstrate that something previously thought impossible is in fact possible.

This is the domain where the hard robots get invented. The humanoid robots that Figure AI and Apptronik are deploying into commercial pilot programs, the autonomous helicopters that Sikorsky and Rain are testing against California wildfires, the agricultural sprayers that Carbon Robotics and Hylio are flying across Iowa cornfields, the autonomous container vessels that Yara and Anduril are scaling into civilian and military maritime use, the Spot quadrupeds that Boston Dynamics has now deployed to oil rigs, talent shows, and presidential residences — every one of these platforms exists because someone at MIT, Carnegie Mellon, Stanford, Berkeley, ETH Zurich, Oregon State, the Florida Institute for Human and Machine Cognition, or one of roughly thirty other research-grade university robotics laboratories spent a decade building the precursor system that the commercial product is descended from. The university research robotics ecosystem is the technological R&D pipeline that the rest of the cluster has been spending. The K-12 robotics competitions feed students into that pipeline. The pipeline feeds commercial products into every other domain in the cluster. The middle layer — the university lab and the NASA mission and the national research facility — is where the technology actually gets invented.

The Agility-Cassie-Digit lineage and the university-to-commercial pipeline

The clearest example of the pipeline in 2026 is Agility Robotics, the company that built the bipedal humanoid platform Digit that is currently being commercially deployed in pilot programs at Amazon warehouses, GXO Logistics facilities, and Spanx distribution centers. Digit is, in lineage terms, the direct commercial descendant of Cassie — the open-source, ostrich-legged dynamic locomotion research platform that Agility’s founders developed at Oregon State University‘s Dynamic Robotics Laboratory under principal investigator Jonathan Hurst. Cassie spun out of OSU in 2017. The intervening eight years have been a series of progressively more capable Cassie iterations, the introduction of upper limbs and a head to create Digit, the build-out of a Salem, Oregon factory capable of producing Digit at volume, and the recent commercial scaling that has put the platform on the floor of working warehouses. The DARPA Robotics Challenge of 2013-2015 — the program that gave rise to the modern humanoid-robot industry — was won by Team KAIST’s DRC-Hubo with MIT‘s Atlas variant, IHMC‘s Atlas, Tartan Rescue’s CHIMP from Carnegie Mellon, and several others in the top finisher list. Every one of those teams was a university or research-institute team operating under DARPA funding. The companies those teams seeded — Boston Dynamics, Apptronik, Figure (whose founder Brett Adcock came from the IHMC orbit), Sanctuary, 1X — have raised, collectively, north of $25 billion in venture capital across the subsequent decade. The research-to-commercial path is a fifteen-to-twenty-year lag, and it is the dominant path by which serious humanoid robotics has reached the market.

The same pipeline runs through every other major commercial robotics platform the cluster has documented. Boston Dynamics Spot is the commercial descendant of BigDog, the DARPA-funded quadruped that Marc Raibert’s group at the MIT Leg Laboratory began developing in the early 2000s before spinning out as Boston Dynamics in 1992 and continuing the work through Google’s ownership (2013-2017), SoftBank’s ownership (2017-2020), and Hyundai’s ownership (2020-present). Anduril Dive-LD descends from the AUV-research work conducted at the Woods Hole Oceanographic Institution and MIT’s Hatx Lab over twenty years. Saildrone descends from Richard Jenkins’s land-yacht and ocean-yacht engineering experiments, ultimately influenced by the Naval Postgraduate School’s autonomous-sailing research. Zipline‘s autonomous-fixed-wing-medical-delivery platform descends from the same family of autonomous-flight research that the Stanford GPS Lab, MIT’s Aerospace Controls Laboratory, and Berkeley’s Center for Information Technology Research in the Interest of Society spent the 2000s and 2010s building. The naming conventions change. The institutional sponsorship changes. The underlying claim — that university research labs are the upstream source of commercial robotics — does not.

The Mars rover program as the boundary case

NASA’s Mars exploration program — and its analogues at the Chinese CNSA, the European Space Agency, the Indian Space Research Organisation, and the Japanese JAXA — represent the extreme upper bound of what scientific research robotics is capable of producing. The current operational fleet on Mars consists of NASA’s Perseverance rover (landed February 18, 2021), NASA’s Curiosity rover (landed August 6, 2012 and still operating), and the Chinese Zhurong rover (landed May 14, 2021, dormant since 2022). The retired Ingenuity helicopter still sits at Valinor Hills, transmitting weather telemetry weekly. Perseverance is, in any quantitative sense, the most sophisticated autonomous robotic platform humans have ever sent to another world: a 2,260-pound, plutonium-238-thermoelectric-generator-powered, six-wheeled rover carrying a 7-foot robotic arm with five degrees of freedom, a 24-tube sample caching system, a 23-camera imaging suite, a ground-penetrating radar, an organic-molecule detector, an X-ray fluorescence spectrometer, and the in-situ resource utilization experiment MOXIE that successfully demonstrated the production of breathable oxygen from Martian atmospheric CO₂. Perseverance is, depending on how you allocate ground-segment costs across the mission lifetime, in the range of a $3 billion robot.

The Mars Sample Return mission — the multi-decade program intended to physically retrieve the samples Perseverance has been collecting and return them to Earth for laboratory analysis — has been the most consequential scientific research robotics program restructuring of the 2020s. The original baseline architecture, finalized in 2022, depended on a NASA-built Sample Retrieval Lander, a Mars Ascent Vehicle, an ESA-built Earth Return Orbiter, and a sample-handling system that combined to roughly $11 billion in lifecycle cost. By mid-2024, that estimate had grown to $11-13 billion with a return-to-Earth date no earlier than 2040. NASA Administrator Bill Nelson initiated a major program review in April 2024 to consider alternative architectures, and in early 2025 NASA selected dual study contracts with Lockheed Martin and a SpaceX-Rocket Lab consortium to evaluate lower-cost commercial alternatives. The resulting program is, as of 2026, fundamentally restructured around a more aggressive commercial-launch baseline and a shorter timeline, with the original Sample Retrieval Lander concept effectively cancelled. The largest scientific research robotics program the United States has ever attempted is being rebuilt, mid-flight, around a fundamentally different commercial-industrial logic than the one that produced Perseverance — which is the same commercial-industrial logic that the rest of this cluster has been documenting in adjacent domains.

The Berkeley A-Lab and the self-driving-laboratory wave

The closest analogue inside terrestrial science to the Mars rover’s autonomous-scientific-decision-making is the self-driving laboratory — the integrated robotic-and-AI platform that designs experiments, runs them, interprets the results, and decides what to do next, without human intervention in the loop. The most publicized example in 2023-2026 was the A-Lab at Lawrence Berkeley National Laboratory, built by Gerbrand Ceder‘s materials science group at UC Berkeley in collaboration with Yan Zeng, Kristin Persson, and a Google DeepMind team. The A-Lab was published in Nature in late November 2023 with a claim that, over 17 days of continuous autonomous operation, the system had performed roughly 21 experiments per day and produced 41 novel inorganic compounds out of an attempted 58 — a 71% success rate, with the inputs drawn from the Materials Project database and DeepMind’s GNoME (Graph Networks for Materials Exploration) catalog of computationally predicted candidate materials. The paper was, in the materials-discovery community, treated as the closest thing to a fully autonomous scientific discovery system anyone had built.

The Nature publication was followed, in early December 2023, by a detailed critique from Robert Palgrave, a materials chemist at University College London, who argued in a widely-circulated X thread that the A-Lab’s automated phase-identification system had misclassified most of the supposed novel compounds and that, on closer inspection of the X-ray diffraction data, the system had not in fact synthesized any new materials. Ceder responded on LinkedIn in late December 2023, defending the underlying methodology while conceding that “a human can perform a higher-quality refinement on these samples.” A more formal critique by Palgrave and collaborators followed in 2024. As of late 2025, the consensus position across the materials-discovery community — captured in a December 2025 MIT Technology Review feature titled “AI materials discovery now needs to move into the real world” — was that despite the A-Lab’s documented technical capability to operate autonomously around the clock, no convincing breakthrough discovery had emerged from any of the major self-driving lab projects, and Ceder himself had taken a sabbatical from Berkeley to become Chief Science Officer at Radical AI, a New York City materials-discovery startup setting up its own self-driving labs in commercial space. The most ambitious autonomous-scientific-discovery program built to date had, in the operational reading, produced infrastructure but not yet results. The cluster’s recurring observation that the publicity has outrun the deliverables applies — perhaps more sharply in this domain than anywhere else.

The broader self-driving-laboratory ecosystem extends well beyond Berkeley. Alán Aspuru-Guzik‘s group at the University of Toronto operates one of the longest-running autonomous chemistry platforms. The Acceleration Consortium at Toronto, launched in 2023 with a $200 million CFREF Canadian federal grant, is building a network of self-driving labs across Canadian universities focused on clean energy materials. Carnegie Mellon‘s autonomous chemistry group, led by Lee Cronin at Glasgow with his “chemputer” platform, operates a different architecture aimed at autonomous synthesis of pharmaceutical molecules. The MIT Bayesian Reaction Optimization group has produced a series of autonomous optimization platforms used in industrial chemistry pilot lines. Opentrons sells open-source pipetting robots into research labs at price points that have made bench automation accessible to academic groups that could not previously afford Hamilton, Tecan, or Beckman Coulter systems. The combined deployed footprint of self-driving labs and bench-automation platforms across academic research is, by 2026, somewhere in the tens of thousands of installations — small compared to the warehouse-robot installed base, but compounding rapidly and concentrated in the highest-value scientific output per dollar spent.

The university lab as humanoid-robot proving ground

The most operationally consequential deployment of commercial robotics into university research environments is the use of Boston Dynamics Spot, ANYbotics ANYmal, and Agility Robotics Cassie/Digit as standard research platforms across roughly two hundred robotics laboratories worldwide. MIT CSAIL operates multiple Spots and a Boston Dynamics Atlas research platform. Stanford’s robotics group operates Spots, an ANYmal, and a fleet of Skydio drones. Carnegie Mellon’s Robotics Institute operates Spots, ANYmal C, an Atlas, a custom CHIMP humanoid descendant, and one of the largest TurtleBot fleets in the United States. ETH Zurich’s Robotic Systems Lab — the academic group that originally spun out ANYbotics — operates ANYmal extensively for legged-locomotion research and is one of the most prolific publishers of legged-robot autonomy research in the world. UC Berkeley’s Robot Learning Lab under Sergey Levine operates a mix of commercial platforms and custom prototypes. Caltech’s Center for Autonomous Systems and Technologies operates Spots and a fleet of custom drones. The Florida Institute for Human and Machine Cognition (IHMC) continues to operate the modified Atlas platforms it inherited from the DARPA Robotics Challenge era. The University of Tokyo, Tokyo Institute of Technology, KAIST, Tsinghua, Shanghai Jiao Tong, the Italian Institute of Technology, EPFL Lausanne, the University of Edinburgh, and TU Delft round out the global research-grade university robotics ecosystem.

The structural argument that makes this deployment matter is that the same Spot platform that reads gauges on BP’s Mad Dog and the same ANYmal that operates on the Petrobras P-71 platform are, fundamentally, refined versions of research platforms that were running open-source autonomy stacks in graduate student labs five to ten years earlier. The commercial product cycle in robotics is, structurally, slower and more research-dependent than the commercial product cycle in software. The next generation of commercial robot — Figure 03, Apptronik Apollo 2, Boston Dynamics Atlas’s hydraulic-to-electric transition, Agility Digit’s next-generation manipulation upgrades — depends in measurable part on what’s happening in graduate-level robotics research right now. The reader who has spent the cluster reading about policing drones and autonomous mining trucks and Trajekt Arc baseball-pitching robots is, in this section, looking at the upstream R&D environment those products are being incrementally drawn out of, by research groups whose annual budgets are typically less than the cost of a single mid-tier commercial humanoid robot.

ROS, TurtleBot, and the open-source infrastructure

The software substrate that makes the entire university-research-robotics ecosystem function is ROS — the Robot Operating System — originally developed at Stanford and Willow Garage in the late 2000s, transferred to the Open Source Robotics Foundation in 2012, and now maintained by Open Robotics, the foundation’s commercial arm that was acquired by Apex AI in late 2022. ROS is the de facto operating system for academic robotics — virtually every research-grade university robotics platform in the world either runs ROS natively or includes a ROS-compatibility layer. The TurtleBot — the open-source mobile robot platform originally designed at Willow Garage in 2010 and now in its TurtleBot 4 generation — is the global standard educational and research mobile-robot platform, with installed-base estimates in the tens of thousands across university labs, community college programs, and high-end K-12 STEM facilities. Clearpath Robotics‘ Husky and Jackal unmanned ground vehicles are the heavier-duty commercial alternatives. Universal Robots’ UR3, UR5, UR10, and UR16 collaborative robotic arms — manufactured in Odense, Denmark, and now owned by Teradyne — are the standard commercial-bench robotic arm in research labs across roughly seventy countries. Franka Emika‘s Panda is the research-grade German alternative. Kinova Robotics‘ Gen3 ultra-lightweight arm is the standard for robotics research requiring portability or human-collaborative operation.

The economic structure of this ecosystem is that the open-source foundation (ROS, TurtleBot, Gazebo simulation) creates the substrate on top of which commercial platforms (UR, Franka, Kinova, Clearpath, Boston Dynamics, ANYbotics, Agility) compete. The substrate is sustained by university research output. The commercial platforms are sold back into the same university labs whose research produced the substrate. The same NVIDIA Jetson and NVIDIA Orin compute platforms that run Disney’s BDX droid and the Skydio X10 also run the typical TurtleBot or Husky deployment. The same lithium-ion battery chemistry, the same rare-earth permanent magnets, and the same semiconductor supply chain that the rest of the cluster has documented show up across the entire research-robotics hardware stack. The component supply chains are convergent. The application domains are divergent.

The drone side: wildlife, environmental, and atmospheric science

The drone-side of scientific research robotics produces a different category of work. The NOAA Hurricane Hunter Reconnaissance Squadron uses unmanned Black Swift S0 and Coyote drones launched into the eyewalls of hurricanes to measure central pressure, wind shear, and storm structure at altitudes and conditions where crewed Lockheed WP-3D Orion aircraft cannot safely operate. The British Antarctic Survey and the U.S. Antarctic Program routinely deploy fixed-wing drones to map ice-shelf calving fronts, count penguin colonies (the Penguin Watch project’s drone fleet has surveyed hundreds of millions of square meters of Antarctic coastline since 2017), and monitor seal populations on remote South Georgia and South Orkney islands. The University of Hawaii flies drones into active volcanic vents at Kīlauea, Mauna Loa, and the Halemaʻumaʻu caldera for plume sampling and lava-flow mapping under conditions that would kill a crewed aircraft. The National Park Service flies drones across Yellowstone for geyser-system monitoring and across Glacier National Park for ice-mass-balance measurements that historically required helicopter-borne teams at orders-of-magnitude higher cost.

In oceanographic research, Saildrone Voyager units are now standard equipment for NOAA fisheries assessments, hurricane-eye intercepts (the first-ever in-storm video from inside a Category 4 hurricane was captured by a Saildrone in Hurricane Sam in 2021), and Arctic methane-flux measurements. REMUS AUVs from HII (formerly Hydroid) are the standard 3-meter-class autonomous underwater vehicle for academic oceanography. WHOI’s Nereus hybrid ROV reached the Mariana Trench in 2009 and operated at full ocean depth before its loss in 2014. The MBARI Mesobot operates at midwater depths tracking individual zooplankton over hour-long observation windows that crewed submersibles cannot sustain. The combined research-grade autonomous-vehicle fleet across all U.S. academic oceanography programs is, by NOAA estimates, in the low thousands of units across the surface, midwater, and deep-ocean tiers — and is the underlying R&D pipeline that produced the maritime-defense-robotics market that Anduril and Saildrone are scaling into U.S. Navy and Allied operational use.

What 2026 looks like in research and university robotics

In 2026, Boston Dynamics Spot, ANYbotics ANYmal, and Agility Robotics Cassie are operating in approximately two hundred university research robotics laboratories worldwide. NASA’s Perseverance rover continues to operate at Jezero Crater, having collected 27 sample tubes that are now slated for a restructured Mars Sample Return program scheduled to return them no earlier than the late 2030s. The Berkeley A-Lab continues to operate, with the Nature-paper controversy unresolved and the underlying autonomous-experimentation infrastructure being adopted by Radical AI, the Acceleration Consortium at Toronto, and a handful of pharmaceutical-industry sites. ROS — the Robot Operating System — runs on virtually every university research-grade robotics platform on Earth. TurtleBot, Husky, Jackal, UR5, Franka Panda, and Kinova Gen3 remain the standard commercial-research hardware. NOAA Hurricane Hunter drones, British Antarctic Survey penguin-counting drones, Saildrone Voyagers in the Arctic and Pacific, REMUS AUVs in academic oceanography, and the long tail of specialized scientific drones across volcanic monitoring, wildlife research, and atmospheric sampling continue to produce the published data that fills the journals. The DARPA Robotics Challenge cohort of 2013-2015 continues to produce the commercial humanoid-robot industry that the cluster’s first post documented. The K-12 FIRST and VEX teams are continuing to feed into the universities. The universities are continuing to feed into the commercial robotics industry. The Mars sample return program is being rebuilt around commercial launch economics.

The research robots in this cluster do something different than every other category of robot the cluster has documented. They are not optimizing margins on warehouse picking. They are not patrolling oil platforms or hospital corridors. They are not delivering blood to remote villages or dropping water on California wildfires. They are not pitching baseballs or dancing on talent shows. The research robots in 2026 are demonstrating, in graduate student labs and DOE-funded national laboratories and NASA mission ops centers and Antarctic field stations, what robots will be capable of in five to fifteen years. Ingenuity proved Mars helicopters are possible. The A-Lab proved autonomous materials synthesis is possible, with the open question of whether it can be made into reliable discovery still being argued in peer-reviewed comments and X threads and conference panels. Cassie proved that bipedal robots can run, and Digit is now stacking warehouse totes. ROS proved that an open-source operating system could become the universal substrate of an entire industry, the same way Linux did for the server market a generation earlier. Saildrone Voyager proved that a 23-foot solar-and-wind-powered sailing vessel can spend twelve months at sea without human intervention and bring back hurricane data the U.S. Navy and NOAA cannot get any other way. The thing every one of these platforms shares is that they were built in research environments where the immediate operational ROI was not the point — the point was to demonstrate that the thing could be done. Once it could be done, the rest of the cluster picked it up and built the product.

The most consequential robots in human history — the ones on Mars, the ones at the bottom of the Mariana Trench, the ones that mapped the genome, the ones that imaged the first black hole, the ones that demonstrated autonomous flight on another world — were all built in scientific research environments by graduate students, postdocs, and mission-systems engineers whose names are mostly not in the press. The 2026 cohort of research robotics is the cohort whose work will, fifteen years from now, populate the rest of this cluster with the next generation of commercial deployments. Ingenuity does not fly anymore. The 17 kilometers it covered, the 72 missions it completed, and the proof-of-concept it delivered for atmospheric flight on another planet are the cluster’s clearest possible example of what research robotics is for. The rest of the robotics industry, in 2026, is built on top of the foundation of work that platforms like Ingenuity, like Perseverance, like Cassie, like ANYmal, like Saildrone, and like the A-Lab were built to test. The graduate students assembling the next generation of those platforms in basement labs at MIT and Stanford and CMU and ETH Zurich and Tokyo and KAIST and Tsinghua are, this spring, doing the upstream work that the rest of American workforce development and the rest of the global robotics market is, in the cluster’s running thesis, structurally dependent on.